Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis

Yuki Kagoya, Yasuhito Nannya, Mineo Kurokawa

Research output: Contribution to journalArticlepeer-review

40 Citations (Scopus)


We performed a meta-analysis of randomized controlled trials comparing thalidomide maintenance with other regimens after induction chemotherapy for multiple myeloma. Overall, 6 trials including 2786 patients were identified. Patients treated with thalidomide maintenance had marginally better overall survival (hazard ratio HR 0.83, P= 0.07). The improvement was especially prominent in a subgroup of studies using corticosteroids with thalidomide (HR 0.70, P= 0.02). Thalidomide improved progression-free survival (HR 0.65, P< 0.01), but had more frequent venous thrombosis (risk difference 0.024, P< 0.05) and peripheral neuropathy (risk difference 0.072, P< 0.01). These results suggest that thalidomide maintenance with corticosteroids is effective in prolonging survival for multiple myeloma.

Original languageEnglish
Pages (from-to)1016-1021
Number of pages6
JournalLeukemia Research
Issue number8
Publication statusPublished - 2012 Aug
Externally publishedYes


  • Corticosteroid
  • Maintenance therapy
  • Meta-analysis
  • Multiple myeloma
  • Randomized controlled trials
  • Thalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis'. Together they form a unique fingerprint.

Cite this